Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.50 |
| ▸ | DRD2 | P14416 | 17/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.50 |
| ▸ | HTR7 | P34969 | 17/20 | 0.50 |
| ▸ | HTR6 | P50406 | 17/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5649054 | 1.00 | HTR1A (0.50) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5647767 | 0.94 | HTR1A (0.50) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| SCHEMBL5647910 | 0.93 | HTR1A (0.49) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5652371 | 0.93 | HTR1A (0.49) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| SCHEMBL5648872 | 0.92 | SIGMAR1 (0.48) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5652479 | 0.92 | SIGMAR1 (0.48) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5649149 | 0.91 | HTR1A (0.48) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| SCHEMBL5650548 | 0.91 | HTR1A (0.48) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5652471 | 0.91 | HTR1A (0.48) | HTR1ADRD2SLC6A4HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL5650454 | 0.90 | SIGMAR1 (0.49) | HTR1ADRD2SLC6A4HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | claimed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | claimed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | HTR1A 1589/4885DRD2 1867/4885SLC6A4 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.